The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancers, either in adjuvant or metastatic settings. Regarding safety, endocrine adverse events (AEs) are some of the most common AEs in ICI-treated patients, with thyroid dysfunction and hypophysitis being the most freq...

Ausführliche Beschreibung